Trial reportKorean journal of ophthalmology : KJO2021
Evaluation of the Safety and Efficacy of Selective Retina Therapy Laser Treatment in Patients with Central Serous Chorioretinopathy.
Trial report in Korean journal of ophthalmology : KJO, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Efficacy and safety of subthreshold micropulse laser for chronic central serous chorioretinopathy: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Interventions for central serous chorioretinopathy: a network meta-analysis.The Cochrane database of systematic reviews · 2025Pooled it
- Comparing treatment outcomes in randomized controlled trials of central serous chorioretinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Pooled it
- Treatment of central serous chorioretinopathy in comparison-microsecond-pulse laser versus photodynamic therapy.Die Ophthalmologie · 2026Review
- Long-term outcomes of titration-guided focal selective retina therapy for chronic central serous chorioretinopathy: retrospective real-world data analysis.BMC ophthalmology · 2026Article
- Comparison of the efficacy of subthreshold micropulse laser versus intravitreal anti-VEGF therapy for chronic central serous chorioretinopathy.Frontiers in medicine · 2026Article
- Therapeutic interventions for chronic central serous chorioretinopathy: a comprehensive assessment of systematic reviews.International journal of retina and vitreous · 2025Review
- [Treatment of central serous chorioretinopathy in comparison-Micropulse laser versus photodynamic therapy].Die Ophthalmologie · 2025Review
- Effect of Focal Laser Photocoagulation on the Ganglion Cell Complex Thickness in Acute Central Serous Chorioretinopathy.Journal of clinical medicine · 2024Article
- Selective retina therapy with real-time feedback-controlled technology in central serous chorioretinopathy: a 24-month follow-up real-world prospective study.BMJ open ophthalmology · 2024Article
- Randomized controlled trials in central serous chorioretinopathy: A review.Eye (London, England) · 2023Review
- Long-Term Multimodal Imaging Analysis of Selective Retina Therapy Laser Lesions.Life (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo assess the safety and efficacy of selective retina therapy (SRT) using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback systems in patients with idiopathic central serous chorioretinopathy (CSC).
methodsThis randomized clinical trial enrolled patients having at least 3-month symptom of CSC. From month 3 visit, all subjects in both groups were eligible for SRT retreatment if they showed persistent or recurrent subretinal fluid (SRF). The primary outcome was complete resolution of SRF by optical coherence tomography at 3 months after treatment. The secondary outcomes were changes in SRF, central macular thickness (CMT) and best-corrected visual acuity at the 1-, 3-, and 6-month examinations.
resultsSixty-eight CSC patients were included (SRT, 31; control, 37). After 1 and 3 months, complete resolution of SRF was achieved in 25.8% and 54.8% of SRT group and 17.6% and 35.1% of controls. The differences were not statistically significant (p = 0.424 and p = 0.142, respectively). However, mixed model for repeated measures analyses showed that the reduction of SRF and CMT were observed earlier in SRT group than in the sham group (least squares mean difference, -59.7 µm; 95% confidence interval, -98.2 to -21.2; p = 0.0029; least squares mean difference -67.0 µm; 95% confidence interval, -104.8 to -29.2; p = 0.0007, respectively). Significant reduction of SRF (≥50% reduction from baseline) was more frequently observed in SRT group (80.6%) than the sham group (44.1%) at month 1 (p = 0.007). Early reduction of SRF and CMT was more abundant in SRT group with symptom duration less than 6 months. Treatment related serious adverse events were not observed.
conclusionsSRT using a Q-switched neodymium-doped yttrium lithium fluoride laser with feedback system was safe in this trial and effective for early resolution of SRF in the CSC patients. Early intervention with SRT can be a safe alternative for patients with acute symptomatic CSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.